
Opinion|Videos|December 18, 2024
Managing CDK4/6 Inhibitor Toxicities and Encouraging Adherence
Author(s)Kevin Kalinsky, MD, MS, Virginia Kaklamani, MD
Panelists discuss how common adverse events (AEs) with CDK4/6 inhibitors in HR+/HER2- early breast cancer (eBC) vary based on treatment and patient population, with strategies for mitigating toxicities, adjusting dosing, and monitoring labs to ensure treatment continuation; they also address approaches to dose reductions, promoting treatment adherence, educating patients about toxicity management, and balancing efficacy, quality of life, and side effect risks, particularly for high-risk patients with no or low nodal involvement.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What adverse events (AEs) do you commonly see in your practice with CDK4/6 inhibitors?
- In your experience, how can these vary based on the treatment and patient population?
- What strategies work best for you to mitigate these toxicities?
- What dosing adjustments or lab monitoring can help manage toxicity for treatment continuation?
- What is your approach to dose reductions or interruptions with CDK4/6 inhibitors when managing AEs? What is your threshold for dose reductions?
- How important is treatment adherence and continuation for maintaining the efficacy benefits?
- What strategies might promote adherence?
- Could you walk through your approach to educating patients about potential CDK4/6 inhibitor toxicity?
- How do you counsel patients on symptom reporting?
- How do you balance efficacy, quality of life, and adverse effect risks when selecting systemic therapy for patients with eBC?
- Does this balance shift for high-risk patients with no or low nodal involvement?
Advertisement
Related to this article

Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.

Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.

The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.

Roswell Park Comprehensive Cancer Center recognized members of its clinical, research and healthcare teams during the second annual Excellence Awards.

The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
5



